Oncopeptides AB (ONCO.SE) is a Swedish pharmaceutical company focused on the development and commercialization of targeted therapies for hematological cancers. With a current market cap of 739.40 million SEK, Oncopeptides is dedicated to advancing innovative treatments to improve the lives of patients. Founded in 2000, it has made significant strides in the field of oncology. The company specializes in developing and commercializing drugs based on its proprietary technology platform, focusing on multiple myeloma and other hematological malignancies.
It went public in 2017 and has since expanded its research and development efforts, aiming to bring novel therapies to the market. The company's commitment to scientific advancements and patient-centric approaches underscores its mission to address the unmet needs of individuals battling hematological cancers.
Oncopeptides AB stock has experienced fluctuations in its share price over the past five years. The highest recorded price during this period was observed at 215 SEK in March 2021, while the lowest point was reached at 3.402 SEK in October 2021. It's important to note that stock prices are subject to change and can be influenced by various factors such as market conditions, industry trends, and company-specific news.
Throughout its history, the company has witnessed notable milestones and achievements, demonstrating its commitment to advancing biopharmaceutical innovation. Investors should stay informed about the company's latest developments, clinical trial results, and regulatory approvals, as these can significantly impact the stock's performance. As the stock market is dynamic and influenced by numerous factors, it's advisable to consult reliable financial sources for real-time updates on Oncopeptides AB stock prices and make informed investment decisions based on current market conditions.
Before considering trading Oncopeptides AB stock, it's important to be aware of its competitors in the pharmaceutical industry. Some notable competitors in the field of targeted therapies for hematological cancers include:
- Johnson & Johnson (JNJ): A diversified healthcare company with a strong presence in the pharmaceutical sector, offering various treatments for hematological malignancies.
- Amgen Inc. (AMGN): A leading biotechnology company that focuses on developing and delivering innovative therapies, including those for hematological malignancies.
- Unilever PLC (UL.US): While primarily known as a consumer goods company, Unilever also operates in the healthcare sector, offering a range of personal care and hygiene products.
- AbbVie Inc. (ABBV): Known for its expertise in immunology and oncology, AbbVie develops therapies for hematological malignancies.
Understanding the competitive landscape and comparing Oncopeptides AB to its peers may provide valuable insights into the market dynamics and help inform investment decisions.
|Swap long||[[ data.swapLong ]] points|
|Swap short||[[ data.swapShort ]] points|
|Spread min||[[ data.stats.minSpread ]]|
|Spread avg||[[ data.stats.avgSpread ]]|
|Min contract size||[[ data.minVolume ]]|
|Min step size||[[ data.stepVolume ]]|
|Commission and Swap||Commission and Swap|
|Trading Hours||Trading Hours|
* The spreads provided are a reflection of the time-weighted average. Though Skilling attempts to provide competitive spreads during all trading hours, clients should note that these may vary and are susceptible to underlying market conditions. The above is provided for indicative purposes only. Clients are advised to check important news announcements on our Economic Calendar, which may result in the widening of spreads, amongst other instances.
The above spreads are applicable under normal trading conditions. Skilling has the right to amend the above spreads according to market conditions as per the 'Terms and Conditions'.
Events that affect Oncopeptides' share prices?
The withdrawal of Pepaxto had a major impact on Oncopeptides’ share prices. In the weeks following the announcement, the prices dropped significantly from 215 SEK to 3.402 SEK. This was due to investors raising concerns about the company’s future prospects and profitability as a result of not having this drug available for sale.
The company’s market capitalization also fell dramatically during this period, as a result of the share price decline. This was a difficult period for Oncopeptides and its shareholders, but the company has taken steps to mitigate any further losses by diversifying their portfolio and investing in new research and development initiatives.
Do Oncopeptides shares pay dividends?
At this stage, shareholders are not expected to receive dividends from their Oncopeptides shares.
However, the company is committed to continuing to invest capital in its innovative projects and deliver value to shareholders. As such, while there is no guarantee of dividend payments in the short-term, it is possible that future profitability may lead to dividends being proposed at a later date.
How can I trade Oncopeptides's share?
If you’re interested in trading Oncopeptides's share, one of the most popular ways to do so is through CFDs (Contracts for Difference). With CFDs, you can trade on a wide range of markets with flexible leverage and minimal costs. You can also speculate on both rising and falling prices, allowing you to take advantage of market movements without having to own the underlying asset.
To get started, you'll need to open an online trading account with a reputable broker and deposit funds into it. Once your account is set up, you can start trading Oncopeptides's share CFDs right away. For more information about how to trade CFDs, please visit our page for more details.
Why Trade [[data.name]]
Make the most of price fluctuations - no matter what direction the price swings and without capital restrictions that come with buying the underlying asset.